End-to-end genomics expertise
- Integrated workflows from sample processing to data delivery
- Scientific support aligned to study objectives and endpoints
- Experience across all phases of clinical development
Advancing Clinical Development through Integrated Genomics
Generate high-quality genomic data with flexible, end-to-end solutions designed to advance biomarker discovery, patient selection, and informed clinical decisions.
A strategic approach to genomics in clinical development
Sequencing alone doesn’t guarantee useful data. To get genomic results you can rely on, you need the right assays, validated workflows, and a clear link between your findings in the lab and what your trial needs to show.
We build genomics strategies around your clinical program, not a one-size-fits-all testing plan. With more than 30 years of experience in human genetic testing, our teams work side by side with yours to turn raw sequence data into clear, clinically meaningful evidence for your trial.
Our global network supports DNA and RNA extraction, next-generation sequencing (NGS), and advanced genomic technologies across oncology, rare diseases, infectious diseases, and beyond. Combining scientific expertise with global operational scale, we deliver genomic data that holds up across sites, stands up to scrutiny, and gives you a solid foundation for the rest of your trial.
Why choose Cerba Research for your genomics programs?
Flexible and tailored genomic solutions
- Fit-for-purpose approaches designed around your study needs
- Custom assay and panel development
- Adaptable solutions across sample types and indications
Advanced technology platforms
- Access to a broad portfolio of genomic technologies
- Scalable solutions supporting studies from early to late phase
- Comprehensive profiling to support biomarker strategies
Collaborative scientific partnership
- Dedicated scientific and operational teams
- Integrated support across biomarker strategy and execution
- Focus on delivering actionable, decision-ready insights
Global laboratory network
- Aligned SOPs and standardized processes across laboratories
- Consistent execution across sites to reduce variability
- Reproducible data supported by shared quality standards
- Centralized oversight for multi-center studies
Supporting your genomics programs
We support your genomics strategy across every phase of clinical development, combining scientific expertise with flexible technologies to deliver high-quality, decision-ready data.
Next-generation sequencing (NGS)
NGS is a core technology for genomic analysis, enabling comprehensive characterization of genetic alterations across a wide range of applications.
We provide flexible NGS solutions designed to align with your study objectives, whether for exploratory biomarker discovery or validated clinical endpoints. Our approach supports consistent, reproducible data generation across sites and studies.
Our experience includes applications in solid tumors, hematological malignancies, liquid biopsies, infectious diseases, and constitutional genomics.
Capabilities include:
- Targeted and broad-panel NGS assays
- Detection of single nucleotide variants (SNVs), insertions and deletions, and copy number variations (CNVs)
- Gene fusion and structural variant analysis
- Tumor mutational burden (TMB) and microsatellite instability (MSI) assessment
- Whole exome and whole genome sequencing
- Liquid biopsy and circulating tumor DNA (ctDNA) analysis
Sample processing and nucleic acid extraction
Reliable genomic data starts with high-quality sample processing. We provide validated workflows for nucleic acid extraction from a wide range of sample types, supporting consistent downstream analysis.
Our harmonized processes and standardized approaches help ensure reproducibility across studies and sites.
Capabilities include:
- DNA, RNA, ctDNA, and cell-free DNA (cfDNA) extraction
- Support for blood, tissue, and liquid biopsy samples
- Automated extraction platforms for consistency and scalability
Custom assay development and biomarker strategy
We work with you to design genomic assays tailored to your study objectives, ensuring your biomarker strategy is aligned from the outset.
From early development through to clinical implementation, our approach focuses on generating data that is fit for purpose and aligned with regulatory expectations.
Capabilities include:
- Custom panel design and assay development
- Assay optimization and fit-for-purpose validation
- Biomarker strategy support aligned to clinical endpoints
Complementary genomic technologies
We complement sequencing with a range of genomic and molecular technologies to support diverse clinical applications and biomarker strategies.
These technologies can be integrated into your study to provide additional layers of biological insight and support multi-modal analysis.
Capabilities include:
- Quantitative polymerase chain reaction (qPCR)
- Digital polymerase chain reaction (dPCR)
- Gene expression and molecular profiling platforms (e.g., nCounter®
analysis system) - Immune repertoire sequencing (with partners)
Related specialized services
Flow cytometry
Analyze cellular populations and immune responses with high-sensitivity flow cytometry solutions.
Anatomic pathology and tissue analysis
Integrate genomic insights with tissue-based biomarker data to generate deeper biological understanding.
Biomarkers
Design biomarker strategies supported by integrated expertise and laboratory solutions across clinical development.
Assay development and technology transfer
Develop and transfer assays aligned to your study requirements and timelines.
Genomics resources and insights
Our Genomics Experience in Oncology
Explore our full range of genomic capabilities, from sequencing technologies to tailored assay development for clinical research.
The Value of Biomarkers from Discovery Through Commercialization
Discover how effective biomarker strategies, including genomics, support more informed decisions and improved clinical outcomes.
Multi-Omics Approaches in Hematological Malignancies
Learn how integrating genomics with complementary biomarker modalities provides deeper insights into disease biology and treatment response.
Precision Medicine for NSCLC: Emerging Trends in Molecular Analysis
Explore how genomic analysis supports patient stratification and precision medicine approaches in non-small cell lung cancer.
